Skip to main content

Table 3 IL-33 Baseline characteristics of patients with lung tissue analysis

From: Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease

Characteristics Never smoker Smoker GOLD 1 GOLD 2 P value
(n = 11) (n = 9) (n = 8) (n = 10)
Age (years) 65.5 ± 8.6 57.9 ± 8.9 63.1 ± 7.5 66.9 ± 5.6 0.08
Male 2 (18.2%) 8 (88.9%) 8 (100.0%) 10 (100.0%) < 0.01
Smoking status      
 Current smoker 0 (0.0%) 2 (22.2%) 1 (12.5%) 3 (30.0%) < 0.01
 Ex-smoker 0 (0.0%) 7 (77.8%) 7 (87.5%) 7 (70.0%)
 Pack years 0.0 ± 0.0 37.9 ± 35.7 31.0 ± 15.1 42.1 ± 22.9 < 0.01
PFT      
 Post BD FVC (L) 2.48 ± 0.4 3.72 ± 0.9 4.30 ± 0.5 3.59 ± 0.7 < 0.01
 Post BD FVC (%) 85.6 ± 10.4 84.9 ± 18.2 100.4 ± 7.4 84.6 ± 10.0 0.03
 Post BD FEV1 (L) 2.00 ± 0.4 3.01 ± 0.6 2.76 ± 0.3 2.10 ± 0.3 < 0.01
 Post BD FEV1 (%) 91.8 ± 14.3 91.2 ± 14.7 87.8 ± 4.7 69.2 ± 8.1 < 0.01
 Post BD FEV1/FVC (%) 80.6 ± 6.9 82.0 ± 6.6 64.1 ± 4.9 59.6 ± 10.0  < 0.01
 RV (%) 102.9 ± 26.5 100.3 ± 30.1 113.1 ± 18.0 121.4 ± 25.6 0.32
IL-33 stain (%) 17.2 ± 9.4 18.5 ± 8.4 24.4 ± 10.9 34.0 ± 12.6 < 0.01
  1. Data are expressed as mean ± SD or No. (%)
  2. GOLD, global initiative for chronic lung disease; PFT, pulmonary function test; BD, bronchodilator; FVC, forced viral capacity; FEV1, forced expiratory volume in 1 s, RV, residual volume; IL, interleukin